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	 Objective(s):	Transforming	growth	factor‐β (TGF‐β)	is	involved	in	colorectal	cancer	(CRC).	The	SD‐208	
acts	as	an	anti‐cancer	agent	in	different	malignancies	via	TGF‐β	signaling.	This	work	aims	to	show	the	
effect	of	manipulation	of	TGF‐β	signaling	on	some	miRNAs	implicated	in	CRC.		
Materials and Methods:	We	investigated	the	effects	of	SD‐208	on	SW‐48,	a	colon	adenocarcinoma	cell	
line.	 The	 cell	 line	 was	 treated	 with	 0.5,	 1	 and	 2	 μM	 concentrations	 of	 SD‐208.	 Then,	 the	 xenograft	
model	of	 colon	cancer	was	established	by	subcutaneous	 inoculation	of	SW‐48	cell	 line	 into	 the	nude	
mice.	The	animals	were	treated	with	SD‐208	for	three	weeks.	A	quantitative	real‐time	PCR	was	carried	
out	 for	 expression	 level	 analysis	 of	 selected	oncogenic	 (miR‐21,	 31,	20a	 and	135b)	 and	 suppressor‐
miRNAs	 (let7‐g,	 miR‐133b,	 145	 and	 200c).	 Data	 were	 analyzed	 using	 the	 2‐∆∆CT	 method	 through	
student’s	t‐test	via	the	GraphPad	Prism	software.	
Results:	Our	results	revealed	that	SD‐208	could	significantly	down‐regulate	the	expression	of	one	key	
onco‐miRNA,	miR‐135b,	 in	either	SW‐48	colon	cells	(P=0.006)	or	tumors	orthotopically	 implanted	in	
nude	mice	(P=0.018).	Our	in	silico	study	also	predicted	that	SD‐208	could	modulate	the	expression	of	
potential	downstream	tumor	suppressor	targets	of	the	miR135b.	
Conclusion: Our	data	provide	novel	evidence	that	anticancer	effects	of	SD‐208	(and	likely	other	TGF‐β	
inhibitors)	may	be	owing	to	their	ability	to	regulate	miRNAs	expression.	
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Introduction	
Colorectal	 cancer	 (CRC)	 is	 the	 second	 leading	
cause	of	cancer	related	death	worldwide,	making	it	a	
fine	 and	 attractive	 area	 for	 oncologists	 to	 study															
(1,	 2).	 In	 numerous	 cancers	 including	 CRC,	 it	 has	
been	 documented	 that	 aberration	 of	 the	 growth	
factor	 signaling	 pathways	 specifically	 transforming	
growth	factor‐β	(TGF‐β)	pathway	play	a	vital	role	in	
tumor	 initiation,	 progression	 and	 metastasis	 (3‐7).	
Therefore,	 it	has	become	a	proper	 target	 for	 cancer	
therapy	(8‐13).	 It	 is	has	been	accepted	 that	a	major	
growth	factor	such	as	TGF‐β,	which	has	a	wide	range	
of	effects	on	key	physiological	events,	must	be	under	
extended	 regulation	 to	 control	 its	 expression	 and	
function.	This	regulation	should	include	mechanisms	
that	 allow	 a	 variety	 of	 effects	 depending	 on	 special	
cellular	and	tissue	contexts	(14‐16).	
Recently,	 a	 new	 layer	 of	 cellular	mechanisms	 as
microRNA	 (miRNA)‐mediated	 gene	 expression	 has	
been	 identified	 that	 is	 implicated	 in	 the																									
post	 transcriptional	 negative	 regulation	 (17‐20).																			
The	 miRNAs	 were	 well‐known	 to	 interact	 with	
signaling	 pathway	 components	 and	 to	 involve	 in	
multiple	 cellular	 processes	 as	 well	 as	 initiation,	
progression	 and	 metastasis	 of	 human	 cancers	 (21‐
25).	Increasing	evidences	have	revealed	that	cancer‐
associated	 miRNAs	 can	 function	 as	 oncogenes	 or	
tumor	suppressors	(18,	20).	The	miRNAs‐mediated	
regulation	networks	can	strictly	influence	the	growth	
factors	 signaling	 pathways	 (24,	 25).	 There	 are	
several	 studies	 showing	 relationship	 of	 TGF‐β	 with	
diverse	microRNAs	 (26‐29).	 In	addition,	 it	has	been	
shown	 that	 basic	 cell	 signaling	 pathways	 adjust													
the	 activity	 of	 the	 related	 components	 in	 miRNAs	
biogenesis	 pathway	 to	 achieve	 a	 fine	 miRNAs	
expression	pattern	(28).	
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Recent	emerging	evidence	suggests	manipulation	
of	growth	 factors	signaling	by	special	 inhibitors	can	
alter	miRNAs	expression	in	cancer	cells	in	vivo	and	in	
vitro	 (30‐35).	 Several	 strategies	 based	 on	 either	
restoration	 of	 silenced	 miRNAs	 or	 inhibition	 of	
overexpressed	 miRNAs	 has	 opened	 a	 new	 area	 of	
research	in	cancer	therapy	including	CRC.	It	has	been	
proposed	that	restoration	of	normal	equilibrium	for	
cancer‐related	 miRNAs	 can	 inhibit	 colon	 tumor	
progression	 (36,	 37).	 On	 the	 other	 hand,	 several	
reports	 imply	 that	 targeting	 of	 TGF‐β	 signaling	
pathway	 at	 late	 stages	 of	 carcinogenesis	 could	 be	 a	
helpful	 tool	 for	 treatment	of	human	cancers	such	as	
CRC,	 glioblastoma	 and	 breast	 cancer	 (4,	 8).	 These	
studies	show	that	a	series	of	TGβRI	kinase	inhibitors	
such	as	SD‐208	could	be	influential	in	treatment	of	a	
range	of	cancers	(12).	Our	aim	was	to	investigate	the	
miRNAs	 (oncogene	 or	 tumor	 suppressor),	 whose	
expression	might	be	altered	due	to	inhibition	of	TGF‐
β	signaling	pathway.	
	
Materials	and	Methods	
Cell	culture	and	treatment	with	SD‐208	
SW‐48	cell	line,	a	human	colon	adenocarcinoma	cell	
line	 (Pasteur	 Institute,	Tehran,	 Iran)	was	grown	 in	25	
cm2	 flask	 (SPL	 Life	 Sciences;	 South	 Korea)	 containing	
RPMI‐1640	 medium	 (Gibco;	 Germany)	 supplemented	
with	 5%	 fetal	 bovine	 serum	 (FBS)	 (Gibco;	 Germany)	
and	 100	 units/ml	 penicillin	 (Gibco;	 Germany).	 Drug	
treatment	 and	 cell	 viability	 assay	 were	 performed	 as	
previously	 explained	 (6).	 Briefly,	 the	 cells	 were	
trypsinized	 in	 exponential	 growth	 phase	 and	 were	
seeded	 in	6‐well	 flat‐bottom	plates	(SPL	Life	Sciences;	
South	Korea)	at	a	density	of	5×105	cells/well	(2000	μl	
media/well).	48	hr	after	treatment	with	0.5,	1	and	2	µM	
concentrations	of	SD‐208,	the	cells	were	harvested	for	
total	RNA	extraction.	
	
Animal	 model	 implanted	 with	 adenocarcinoma	
cell	line	(SW‐48)	and	treatment	protocol	
The	protocol	for	establishing	the	xenograft	model	of	
colon	 cancer	was	 approved	 by	 the	 Committee	 on	 the	
Ethics	 of	Animal	 Experiments	 of	 Tehran	University	 of	
Medical	Sciences	(Ethical	Code	Number;	ERC/S/277)	as	
previously	 described	 (6).	 6‐week‐old	 female	 athymic	
C56BL/6	 nude	mice	 (n=	 8	 per	 group)	 were	 obtained	
from	Omid	Institute	 for	Advanced	Biomodels	(Tehran,	
Iran).	 After	 cell	 inoculation,	 xenograft	 tumors	 were	
allowed	to	achieve	a	size	of	80	mm3.	Then,	the	animals	
were	randomly	divided	into	two	groups	of	8	to	receive	
either	 SD‐208	 (50	 mg/kg/d)	 or	 vehicle	 (DMSO‐
containing	 deionized	 water)	 orally	 for	 three	 weeks.	
Obtained	 tumors	 after	 isolating	 from	 animals,	 were	
fixed	in	formalin	or	frozen	for	histological	staining	and	
RNA	extraction,	respectively.		
	
Histopathological	diagnosis	of	colon	tumors		
To	confirm	colon	adenocarcinoma,	tumor	tissues	
tissues	were	excised	and	subjected	to	hematoxylin	and	
eosin	 (H&E)	 staining	 (Dako,	 Denmark)	 as	 previously	
described	(6).		
	
Total	 RNA	 extraction	 from	 cultured	 and	 tumor	
tissues	
Either	 SW‐48	 cells	 or	 tumor	 tissues	 at	 the	
mentioned	time	points	after	treatment	with	SD‐208,	
were	subjected	for	total	RNA	extraction	using	TRIzol	
reagent	 (Invitrogen;	 Germany)	 according	 to	 the	
manufacturer’s	instructions.	Extracted	total	RNA	was	
stored	at	‐80	°C	until	use.	
	
miRNA	 expression	 analysis	 by	 reverse‐
transcription	(RT)	real‐time	PCR	
Four	miRNAs	as	potential	onco‐miRs (miR‐21,	 	31,	
20a,	 135b)	 and	 four	miRNAs	as	potential	 suppressor‐
miRs	 (let7‐g,	miR‐133b,	 145,	 200c)	 involved	 in	 colon	
cancer,	were	 selected	 from	 the	 Sanger	 Center	miRNA	
Registry	 at	 http://www.sanger.ac.uk/Software/Rfam/	
mirna/index.shtml.	MicroRNA	expression	was	analyzed	
by	 real‐time	 quantitative	 polymerase	 chain	 reactions	
(qPCR)	 using	 the	 SYBR	 Green	 method	 (Parsgenom,	
Iran).	 After	 polyadenylation	 of	 total	 RNA	 and	 cDNA	
synthesis,	 miRNAs	 were	 expanded	 by	 the	 specific	
primers	 for	 mature	 forms	 according	 to	 the	
manufacturer’s	 instructions.	 Real‐time	 PCR	 was	
performed	on	a	Bio	Rad	CFX96	Real‐Time	PCR	System.	
RNU6B	was	used	as	an	endogenous	(internal)	control,	
and	 the	 data	 were	 normalized	 compared	 to	 this	
housekeeping	 gene.	 All	 reactions	 were	 performed	 in	
triplicate	 and	 the	 absence	 of	 contamination	 was	
verified	using	non‐template	controls.	PCR	products	also	
were	visualized	by	electrophoresis	on	a	2%	agarose	gel.	
	
Statistical	analysis		
Data	 analysis	 was	 performed	 using	 the	 2‐∆∆cCT	
method.	 The	 standard	 error	 of	 means	 was	 computed	
and	 analysis	 of	 variance	 (ANOVA,	 Tukey’s	 post	 tests)	
completed	 via	 GraphPad	 Prism	 5.0	 software.	P-values	
less	than	0.05	were	considered	to	 indicate	statistically	
significant	differences	between	data	sets.	
	
Results	
SD‐208	toxicity	effects		
To	assess	the	potential	toxicity	effects	of	SD‐208,	the	
expression	 levels	 of	 miRNAs	 was	 examined	 by	 real	
time	 RT‐PCR	 (Table	 1).	 Then	 the	 appropriate	
numbers	of	SW‐48	cells	were	injected	into	8	mice	to	
develop	tumors.	Following	SD‐208	treatment	period,	
we	 could	 not	 observe	 any	 changes	 in	 animal	
behavior,	 body	 weight	 or	 lifespan	 compared															
to	 controls.	 Also	 all	 mice	 with	 an	 observed	 tumor	
growth	survived	with	a	balanced	diet.	These	data	
suggest	 that	 SD‐208	 lacks	 toxic	 effects	 on	 animals	
(data	not	shown).	
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Table	1.	miRNAs	differentially	expressed	 in	SW‐48	cells	after	48	
hr	treatment	with	SD‐208	
	
miRNA	 Fold	change P-value
miR‐21	
miR‐31	
miR‐20a	
miR‐135b	
let7‐g	
miR‐133b	
miR‐145	
miR‐200c	
‐0.923	
‐0.938	
‐0.918	
‐0.519	
+1.1	
+1.07	
+1.09	
+1.12	
0.401
0.467	
0.249	
0.006**	
0.099	
0.163	
0.15	
0.135
	
Colon	adenocarcinoma	confirmation	
The	H&E	staining	confirmed	marked	cellularity	with	
significant	 hyperchromatism	 and	 pleomorphism	
(Figure	1).	The	pattern	of	adenocarcinoma	was	alike	to	
the	human	origin	(Figure	1	A,	B).	
	
Expression	 pattern	 of	 selected	 onco/suppressor	
miRNAs	in	colon	adenocarcinoma	SW‐48	cell	line	
Real‐time	 PCR	 analysis	 detected	 differentially	
expression	of	all	selected	miRNAs	in	SW‐48	cell	 line	
(Table	2).	Among	the	studied	miRNAs,	miRNA‐135b	
and	let7‐g	expressed	at	the	highest	and	lowest	levels,	
respectively	(Figure	2).		
	
Alteration	of	the	miRNAs	expression	resulted	by	
SD‐208	treatment	
Evaluation	of	miRNAs	expression	by	q‐PCR	showed	
that	 the	 expression	 of	 miR‐135b	 significantly	 down‐
regulated	 after	 treatment	 by	 SD‐208	 (P=0.006,	 Figure	
3A).	 In	 the	 tumors	 treated	 with	 SD‐208,	 miR‐135b	
expression	 also	 was	 down‐regulated	 significantly	
(P=0.018),	 compared	 to	 control	 tumors	 (Figure	 3B).	
Our	results	showed	that	all	the	treated	tumors	express	
a	 lower	 number	 of	miR‐135b,	 but	 not	 other	miRNAs,	
compared	 to	 the	 control	 tumors.	 However,	 there	was	
no	change	 in	cell	proliferation	or	tumor	size	(data	not	
shown).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
Figure	 1.	 Representative	 results	 of	 orthotopic	 colon	 tumor	 in	
nude	 mice	 and	 pathological	 confirmation.	 Nude	 mice	 bearing	
developed	 SW‐48	 tumors	were	 divided	 into	 two	 groups:	 SD‐208	
treatment	 (A)	and	vehicle	 (B).	Hematoxylin	and	eosin	staining	of	
tumor	 tissues	 confirmed	 colon	 adenocarcinoma	 in	 both	 treated	
(A)	 and	 non‐treated	 (B)	 tumor‐bearing	 mice.	 The	 staining	
demonstrates	marked	cellularity	with	profound	hyperchromatism	
and	 pleomorphism	 (arrows)	 and	 low	 differentiated	 tumor	 cells	
similar	to	human	colon	cancer	
Table	 2.	 miRNAs	 differentially	 expressed	 in	 SW‐48‐derived	
tumors	after	treatment	with	SD‐208	
	
miRNA	 Fold	change	 P-value
miR‐21	
miR‐31	
miR‐20a	
miR‐135b	
let7‐g	
miR‐133b	
miR‐145	
miR‐200c	
‐0.923	
‐0.938	
‐0.918	
‐0.519	
+1.1	
+1.07	
+1.09	
+1.12	
0.401	
0.467	
0.249	
0.006**	
0.099	
0.163	
0.15	
0.135	
	
	
Prediction	of	the	target	genes	of	miR‐135b	using	
bioinformatics	analysis	
In	 order	 to	 determine	 the	 biological	 function	 of													
the	 down‐regulated	 miRNA,	 miR‐135b,	 we	 further	
predicted	 the	 putative	 downstream	 targets	 of	 this	
miRNA.	We	focused	our	attention	on	miR‐135b	because	
it	was	the	only	miRNA	affected	by	SD‐208	either	in	vitro	
or	 in	 vivo.	 In	 silico	 analysis	 using	 TargetScan	
(http://www.targetscan.org/)	 showed	 that	 miR‐135b	
potentially	targets	transcripts	encoding	known	tumor‐
suppressor	 factors,	 such	 as	 APC	 (adenomatosis	
polyposis	 coli),	 FOXO1	 (forkhead	 transcription	 box1),	
RUNX1	(runt‐related	transcription	factor	1)	and	ESRRA	
(estrogen‐related	receptor	alpha).		
	
Discussion		
In	 this	 study,	we	evaluated	 the	 effect	 of	 a	TGF‐β	
receptor	kinase	inhibitor,	SD‐208,	on	some	potential	
onco/suppressor‐miRNAs	expression	in	CRC.	SD‐208	
is	 a	 TGF‐β	 signaling	 pathway	 inhibitor	 that	 could	
exert	 anticancer	 effects	 on	 several	 tumor	 cells	 by	
reduction	of	growth	rate	or	modification	of	other	cell	
functions	(6,	9,	12).	Some	investigators	revealed	SD‐
208	 reduces	 tumor	 growth	 and	 metastasis	 in	
different	 cancers	 (9,	 12),	 whereas,	 others	 showed	
this	 agent	 regulates	 the	 growth	 of	 tumors	 without	
changes	 in	 proliferation,	 apoptosis	 or	 angiogenesis	
and	cannot	reduce	proliferation	of	cells	(8).	Another	
study	 reported	 that	 SD‐093	 (as	 an	 SD‐208	 analog)	
failed	 to	 alter	 morphology	 and	 growth	 rate	 of	
pancreatic	 carcinoma	 cells	 (38).	 Also	 it	 has	 been	
reported	that	SD‐208	has	no	effect	on	the	growth	of	
	
	
	
Figure	2.	 Electrophoresis	 of	miRNAs	 genes	pattern	 expressed	 in	
SW‐48	 cell	 line.	 As	 shown,	 all	 selected	 onco/suppressor	miRNAs	
express	differentially	in	SW‐48	cell	line	
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Figure	3.	Modulation	of	miR‐135b	expression	caused	by	SD‐208	treatment.	The	expression	of	miR‐135b	significantly	was	down‐regulated	
either	in	cell	culture	(A)	or	developed	tumors	(B)	in	SD‐208	groups	compared	to	controls	
	
primary	 and	 metastatic	 R3T	 mammary	 tumors	 in	
athymic	nude	mice	 (9).	 These	 findings	 indicate	 that	
anti‐cancer	 effect	 of	 SD‐208	 may	 be	 not	 due	 to	
suppression	 of	 cell	 growth	 and	 proliferation	 (36).	
Since	efficacy	of	this	inhibitor	is	a	controversial	issue	
in	 cancer	 treatment,	we	 hypothesized	 the	 unknown	
mechanism(s)	 including	 alteration	of	 cancer‐related	
miRNAs	might	be	involved.		
Several	 chemopreventive	 agents	 have	 been	
shown	 to	 modulate	 the	 expression	 of	 numerous	
miRNAs	 in	 cancer	 cells	 that	 lead	 to	 sensitization	 of	
cancer	 cells	 to	 chemotherapeutic	 agents	 (39,	 40),	
suggesting	 the	 potential	 of	 miRNAs	 as	 targets	 for	
anti‐cancer	drugs	 (18,	 20).	Hence,	 evaluation	 of	 the	
possible	 effects	 of	 chemotherapeutic	 drugs	 on	 the	
expression	profile	of	miRNAs	may	have	an	important	
outcome	for	cancer	therapy	strategies	(21,	33).		
Although	 a	 number	 of	 studies	 have	 shown	 that	
chemotherapy	 drugs	 alter	 miRNAs	 expression	 in	
many	cancer	cells,	there	is	no	report	on	the	effect	of	
TGF‐β	 receptor	 kinase	 inhibitors	 on	 miRNAs	 in	
human	 CRC.	 We	 selected	 some	 miRNAs	 that	 have	
already	 been	 confirmed	 to	 function	 as	 onco‐miR	
(miR‐21,	 miR‐31,	 miR‐20a,	 and	 miR‐135b)	 or	
suppressor	 miR	 (miR‐133b,	 miR‐145,	 miR‐200	 and	
let7‐g)	in	CRC	(36‐39).	The	present	study	focused	on	
the	 alteration	 of	 these	 miRNAs	 in	 colon	 cancer	
treated	by	SD‐208.	 
Expression	 analysis	 of	 miRNAs	 by	 a	 q‐PCR	
revealed	 that	 expression	 of	 miR‐135b	 significantly	
down‐regulated	after	in	vitro	treatment	with	SD‐208	
(P=0.006).	In	the	tumor	tissues	treated	with	SD‐208,	
miR‐135b	 expression	 significantly	 down‐regulated,	
also.	The	results	showed	that	all	 the	 treated	tumors	
significantly	expressed	a	lower	number	of	miR‐135b,	
but	 not	 other	 oncogenic‐miRNAs,	 compared	 to	
controls	(P=0.018).	However,	there	was	no	change	in	
cell	proliferation	or	tumor	size.		
Interestingly,	the	miR‐135b	has	been	documented	
as	 a	 tumor	 promoting	 factor	 and	 to	 play	 a	 role	 in	
migration	and	metastasis	in	different	cancers	as	well	
as	CRC	 (37‐39).	 In	order	 to	 address	 the	question	of	
how	 can	 the	 possible	molecular	mechanisms	 of	 the	
miR‐135b	on	CRC	cell	signaling	pathways	be	defined,	
we	 performed	 an	 in‐silico	 study.	 In	 silico	 analysis	
using	 TargetScan	 (http://www.targetscan.org/)	
showed	 that	 miR‐135b	 potentially	 targets	 key	
tumor‐suppressor	 genes	 involved	 in	 CRC:	 APC	 and	
FOXO1.	 APC	 and	 FOXO1	 genes	 have	 also	 been	
validated	 as	 targets	 of	 miR‐135b	 using	 luciferase	
reporter	assay	(41),	hence,	we	would	like	to	discuss	
these	genes	whose	functions	could	potentially	affect	
the	cell	signaling	in	CRC.	
APC	 gene	 acts	 a	 tumor	 suppressor	 the	
inactivation	 of	 which	 is	 the	 key	 initiating	 event	 in	
colorectal	 carcinogenesis	 (42).	 Recently,	 one	 study	
demonstrated	that	up‐regulation	of	miR‐135b	in	CRC	
is	associated	with	low	APC	mRNA	levels	(42).	In	the	
present	 study,	 we	 advocate	 a	 novel	 molecular	
mechanism:	 a	 kinase	 inhibitor	molecule	 can	 reduce	
miR‐135b	expression,	by	which	APC	activation	could	
be	mediated.		
Moreover,	 it	 has	 been	 reported	 that	 miR‐135b	
affects	 FOXO1	 as	 an	 endogenous	 target	 and	
suppresses	 protein	 expression.	 Several	 lines	 of	
evidence	 indicate	 that	 FOXO	 transcription	 factors	
might	play	an	 important	role	 in	tumor	development	
(41,	 43).	 On	 the	 other	 hand,	 FOXO1	 alteration	 by	
miR‐135b	can	affect	sensitivity	to	chemotherapeutic	
drugs,	 such	 that	 tumor	 cells	 overexpressing	 miR‐
135b	 were	 more	 resistant	 to	 specific	 anticancer	
drugs.	These	results	suggest	the	possibility	that	miR‐
135b	 may	 confer	 chemoresistance	 to	 tumor	 cells	
through	 FOXO1	 modulation	 (41).	 Therefore,	 it	 is	
rational	 to	 hypothesize	 that	 the	 properties	 of	 anti‐
cancer	 drugs	 may	 be	 related	 to	 their	 alteration	 of	
miRNA	profiles	(43,	44).	For	example,	suppression	of	
miR‐21	 has	 been	 shown	 to	 sensitize	MCF‐7	 cells	 to	
topotecan	(44).	As	well,	5‐FU	was	reported	to	be	able	
to	 modify	 the	 expression	 of	 several	 miRNAs	 in	
human	 colon	 cancer	 cells	 (44).	Similar	 studies	 exist	
for	 the	 drugs	 gemcitabine,	 doxorubicin	 and	
tamoxifen	(38).		
Overall,	we	primarily	predicted	that	combination	
of	SD‐208	and	one	anticancer	drug	such	as	5‐FU,	may	
show	stronger	inhibition	of	colon	tumor	cell	growth	
by	 modification	 of	 onco‐miRs.	 Additionally,	 as	 a	
novel	approach	in	CRC	therapy,	pre‐treatment	by	SD‐
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208	 could	 improve	 chemosensitivity	 in	 resistant	
cancerous	 cells.	 However,	 the	mechanism	 by	which	
these	 agents	 alter	 miRNA	 expression	 may	 be	
dependent	on	genomic	context.		
	
Conclusion		
The	receptor	kinase	inhibitor	SD‐208	may	partially	
inhibit	colon	tumorigenesis	as	well	as	chemoresistance	
by	 alteration	 of	 miRNAs.	 Hence,	 the	 TGβRI	 kinase	
inhibitor‐based	 treatment	 may	 possibly	 uphold	
chemosensitivity	in	resistant	colon	cancer	cells.	
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